Article Contents ::

Details About Generic Salt ::  Hepatiti

Main Medicine Class:: Immune serum   

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

 

Drugs Class ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Indications for Drugs ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Dose ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Contraindication ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Precautions ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Side Effects ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Mode of Action ::  

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Interactions ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

Drug Assesment ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Storage/Management ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Drug Notes ::

(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum

 

 Action Directly neutralizes hepatitis B virus.

 

 Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.

 

 Contraindications None well documented.

 

 Route/Dosage

Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.

 

 Interactions

Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.

 

 Precautions

Pregnancy: Category C. Lactation: Undetermined.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Inspect solution for particulate matter and discoloration before administration.
  • Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
  • Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
  • Refrigerate vials. Do not freeze.

 

 Assessment/Interventions

  • Obtain complete history, including drug history and any known allergies.
  • Check patient’s immunization history to verify that administration regimen is being followed.
  • Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
  • Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
  Pain, tenderness

 

 Patient/Family Education

  • Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
  • Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
  • Provide patient or parent with immunization history record and record this injection in patient’s medical records.
  • Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
  • Inform parent or patient of schedule for vaccination program if necessary.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.